Evidence map›Paper›PMID 32853832›Full record

ArticleBiomaterials2020

Nanoparticle-based "Two-pronged" approach to regress atherosclerosis by simultaneous modulation of cholesterol influx and efflux.

Hongliang He, Jing Wang, Paul J Yannie, William J Korzun, Hu Yang, Shobha Ghosh

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Review
  17. Self-oxygenation mesoporous MnOJournal of nanobiotechnology · 2022
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hongliang HeDepartment of Internal Medicine, VCU Medical Center, Richmond, VA, 23298, USA; Department of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA, 23219, USA.
Jing WangDepartment of Internal Medicine, VCU Medical Center, Richmond, VA, 23298, USA.
Paul J YannieHunter Homes McGuire VA Medical Center, Richmond, VA, 23249, USA.
William J KorzunDepartment of Clinical and Laboratory Sciences VCU Medical Center, Richmond, VA, 23298, USA.
Hu YangDepartment of Chemical and Life Science Engineering, Virginia Commonwealth University, Richmond, VA, 23219, USA; Massey Cancer Center, Virginia Commonwealth University, Richmond, VA, 23298, USA; Department of Pharmaceutics, Virginia Commonwealth University, Richmond, VA, 23298, USA. Electronic address: hyang2@vcu.edu.
Shobha GhoshDepartment of Internal Medicine, VCU Medical Center, Richmond, VA, 23298, USA; Hunter Homes McGuire VA Medical Center, Richmond, VA, 23249, USA. Electronic address: shobha@vcu.edu.
Hunter Holmes McGuire VA Medical Center · USVirginia Commonwealth University · USVirginia Commonwealth University Medical Center · US

Funding

Modulating Macrophage Function in Atherosclerosis by Functionalized NanoparticlesR01HL140684 · NHLBI · VIRGINIA COMMONWEALTH UNIVERSITY · PI GHOSH, SIDDHARTHA S, YANG, HU · 2018 to 2021
$2.5M
Triple Quadrupole - Ion Trap Hybrid LC/MS/MS SystemS10RR027926 · NCRR · WAYNE STATE UNIVERSITY · PI MADDIPATI, KRISHNARAO · 2010 to 2010
$425k
Cholesterol regulation of Macrophage Inflammation and Vascular DiseasesI01BX002297 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI GHOSH, SHOBHA · 2016 to 2019
–
BLRD VA I01 BX002297NCRR NIH HHS S10 RR027926NHLBI NIH HHS R01 HL140684
6 · The paper itself

Abstract

Reduction of lipoprotein uptake by macrophages and stimulation of cholesterol efflux are two essential steps required for atherosclerotic plaque regression. We used the optimized mannose-functionalized dendrimeric nanoparticle (mDNP)-based platform for macrophage-specific delivery of therapeutics to simultaneously deliver SR-A siRNA (to reduce LDL uptake) and LXR ligand (LXR-L, to stimulate cholesterol efflux) - a novel "Two-pronged" approach to facilitate plaque regression. mDNP-mediated delivery of SR-A siRNA led to a significant reduction in SR-A expression with a corresponding decrease in uptake of oxLDL. Delivery of LXR-L increased expression of ABCA1/G1 and cholesterol efflux. Combined delivery of siRNA and LXR-L led to a significantly greater decrease in macrophage cholesterol content compared to either treatment alone. Administration of this in vitro optimized formulation of mDNP complexed with SR-A-siRNA and LXR-L (Two-pronged complex) to atherosclerotic LDLR-/- mice fed western diet (TD88137) led to significant regression of atherosclerotic plaques with a corresponding decrease in aortic cholesterol content.

Indexed as

AtherosclerosisNanoparticlesAnimalsATP Binding Cassette Transporter 1CholesterolLiver X ReceptorsMiceMice, KnockoutATP Binding Cassette Transporter 1CholesterolLiver X ReceptorsAtherosclerosisCholesterol effluxCholesterol influxMacrophageNanoparticlePlaque regression

Identifiers

PMID32853832
PMCPMC7530139
OpenAlexW3049755106

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.